Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications

Summary

This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications

Timeline

Start

2022-11-07

Primary completion

2025-03-31

Completion

2025-07-08

Outcome

Met primary endpoint

registry analysis (superiority test); DB Rimegepant vs DB Placebo; p <0.0001; Least square mean (LSM) Difference -1.6 (95% CI -2.13 to -1.15); Mixed Models Analysis NCT05518123 ↗

Publications

• Pozo-Rosich P, Gien Lopez JA, Lisewski P, Aslan AN, Seehra H, Thiry A, Abraham L, Ramirez LM, Fountaine R, Fullerton T. Does rimegepant prevent migraine attacks in people who have not found other treatments taken by mouth (orally) to work well? A plain language summary of clinical study findings. Pain Manag. 2026 Jun;16(6):539-550. doi: 10.1080/17581869.2026.2646702. Epub 2026 Apr 28.
• Pozo-Rosich P, Lopez JAG, Lisewski P, Aslan AN, Seehra H, Thiry A, Abraham L, Ramirez LM, Fountaine R, Fullerton T. A phase 4, randomized, double-blind, placebo-controlled trial evaluating the efficacy and tolerability of rimegepant for the prevention of episodic migraine in adults with a history of inadequate response to traditional oral preventive medications. Cephalalgia. 2025 Nov;45(11):3331024251391378. doi: 10.1177/03331024251391378. Epub 2025 Nov 18.

Drugs

Indications